🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation

Recruitingn/aAges 18 Years - anyAllPeking University People's Hospital
NCT07905066 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory complication that can occur after allogeneic hematopoietic stem cell transplantation. Its signs can overlap with those of infection and other transplant complications, making early recognition difficult. This study will examine whether changes in routine blood tests and clinical information can help identify patients who may develop HLH during the following seven days. The study will combine a review of existing medical records with prospective follow-up at participating hospitals in China. Approximately 20,000 adults undergoing their first allogeneic transplantation will be included, with approximately 400 post-transplant HLH cases expected. Historical records will be used to develop the prediction model. Data from independent centers and prospectively enrolled patients will be used to validate the model. Participants w

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older at first allogeneic hematopoietic stem cell transplantation. First allogeneic hematopoietic stem cell transplantation performed at a participating center within the study period. Verifiable transplantation date and basic clinical information. Written informed consent from the participant or legally authorized representative for prospective participation. Retrospective records are used under the applicable ethics-approved consent or waiver procedures. Exclusion Criteria: * Autologous transplantation or transplantation other than hematopoietic stem cell transplantation. HLH diagnosed before transplantation, or transplantation performed primarily for HLH. Previous allogeneic hematopoietic stem cell transplantation. Patient identity, transplantation date, or key outcome information cannot be verified. Explicit refusal to participate or to permit the use of clinical information for this study.
💊

What it tests

  • Not listed
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy